Developing Therapeutic Treatments for Chronic Neuropathic Pain and Sensorineural Hearing Loss

Our Company

Hoba Therapeutic is an early-stage biotech based in Denmark developing innovative treatments for chronic pain disorders and sensorineural hearing loss - indications with a high unmet medical need for safe and efficacious treatments for millions of patients worldwide.


Our science is based on the discovery of a novel family of endogenous human proteins: meteorin and cometin. These neurotrophic factors are involved in the development, growth, survival, and maintenance of nerve cells, supporting glial cells and sensory pathways.

Our Pipeline

Hoba Therapeutics holds the right to two novel biopharmaceutical drugs

  • HB-086 is in late preclinical development for neuropathic pain. The target indications are Chemotherapy-Induced Peripheral Neuropathy (CIPN) and trigeminal neuralgia.
  • HB-097 is in preclinical development for sensorineural hearing loss. The target indications are ototoxic and noise-induced hearing loss.

Latest News

1 March 2024

Hoba Therapeutics announces the appointment of Jean Combalbert as Chair of the Board of Directors.

11 December 2023

Hoba Therapeutics raises EUR 23 million in a Series A to advance new drug candidate against chronic neuropathic pain. The financing was co-led by Indaco Venture Partners and Medical Incubator Japan, and included investments from Novo Holdings, Eir Ventures, the Export and Investment Fund of Denmark (EIFO) and The European Innovation Council Fund.

6 July 2022

Eir Ventures, in partnership with the Danish Growth Fund, has completed an internal purchase of shares from Borean Innovation and is now an investor in Hoba Therapeutics.